Vaccine News and Research

RSS

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.

Circadian rhythms control killer cells in the immune system

According to an analysis of data humans’ ability to combat diseases may largely depend on day-to-day circadian cycles than previously believed.

13 Jan 2021

Scientists identify the sensor in human lungs that detects SARS-CoV-2

Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified the sensor in human lungs that detects SARS-CoV-2 and signals that it's time to mount an antiviral response.

13 Jan 2021

Novel treatments could cut the death rate from dengue, Zika, West Nile viruses

A new study led by researchers from The University of Queensland (UQ) could help identify new therapies to reduce the global death rate caused by Zika, West Nile, and dengue viruses.

8 Jan 2021

Gut cells raise alarm during parasite invasion

To effectively combat an infection, the body first has to sense it's been invaded, then the affected tissue must send out signals to corral resources to fight the intruder.

29 Dec 2020

Kobe University and Sysmex conduct joint research on new blood test for identifying COVID-19

Kobe University and Sysmex Corporation have been engaged in joint research on the ELISPOT method, a new blood test for identifying the novel coronavirus disease (COVID-19).

28 Dec 2020

Scientists discover new class of compounds for combating antimicrobial resistance

Wistar Institute scientists have discovered a new class of compounds that uniquely combine direct antibiotic killing of pan drug-resistant bacterial pathogens with a simultaneous rapid immune response for combatting antimicrobial resistance (AMR). These finding were published today in Nature.

24 Dec 2020

Study reveals lower transfer of protective SARS-CoV-2 antibodies via the placenta

Recent analyses indicate that pregnant women and newborns may face elevated risks of developing more severe cases of COVID-19 following SARS-CoV-2 infection.

24 Dec 2020

Researchers identify suitable biocatalyst for designing COVID-19 vaccine

The chemical substance class of nucleosides is attracting a great deal of interest, and this can be attributed to the ongoing COVID 19 pandemic.

17 Dec 2020

Study: DOT1L enzyme is essential for humoral immune responses

Communication, serendipity and an enzyme called DOT1L have all combined to produce some exciting findings into the immune system's B cells and T cells by two groups of Monash Biomedicine Discovery Institute (BDI) scientists.

17 Dec 2020

Gene expression database sheds light on pneumococcal infection

Researchers at the University of Maryland School of Medicine published one of the most comprehensive analyses of how genes get expressed during infection (known as a transcriptome).

16 Dec 2020

Study may lead to new approaches to protect older individuals from viruses

A drug that boosts the removal of cellular debris in immune cells may increase the protective effects of vaccines in older adults, a study published today in eLife shows.

16 Dec 2020

MMR vaccine may be protective against COVID-19, study shows

The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against COVID-19. In a new study published in mBio, an open-access journal of the American Society for Microbiology, researchers provide further proof of this by showing that mumps IgG titers, or levels of IgG antibody, are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with the MMR II vaccine produced by Merck. MMR II contains the Edmonston strain of measles, the Jeryl Lynn (B-level) strain of mumps, and the Wistar RA 27/3 strain of rubella.

23 Nov 2020

Study: 95.5% of current entries in GISAID lack relevant COVID-19 patient information

A new study led by Australia's national science agency CSIRO, has found 95.5 per cent of current entries in GISAID, the world's largest novel coronavirus genome database, do not contain relevant patient information -- a critical piece of the puzzle to understand the virus and how it is evolving.

17 Nov 2020

Mutations in SARS-CoV-2 spike protein may improve monoclonal antibody resistance

A recent paper examines a mutation of the spike protein of SARS-CoV-2 that has been observed to have arisen independently twice.

10 Nov 2020

Pfizer and BioNTech COVID-19 vaccine is found to be 90% effective

Pfizer and BioNTech have today announced their new vaccine candidate (BNT162b2) is 90% effective against SARS-CoV-2.

9 Nov 2020

Genetically edited form of herpes simplex virus outperforms key vaccine candidate

A genetically edited form of a herpes simplex virus -- rewired to keep it from taking refuge in the nervous system and eluding an immune response -- has outperformed a leading vaccine candidate in a new study from the University of Cincinnati, Northwestern University and the University of Nebraska-Lincoln.

9 Nov 2020

Researchers use new technology to design promising vaccine for COVID-19

A new nanoparticle vaccine candidate developed for the novel coronavirus creates virus-neutralizing antibodies in mice at levels that are 10 times higher than is observed in individuals, who have recovered from the COVID-19 disease.

4 Nov 2020

Study shows memory T cells are formed earlier than previously thought

A person will acquire immunity to a specific disease when T cells develop into memory cells after making contact with pathogens.

4 Nov 2020

“Nanobiologic” immunotherapy can train the immune system to eliminate tumor cells

Until recently, it was believed that the innate immune system, the body's first line of defense, lacked the ability to remember pathogens like the adaptive immune system.

2 Nov 2020

Individuals infected with mild-to-moderate COVID 19 mount a robust antibody response

The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 28, in the journal Science.

29 Oct 2020